METASTATIC PROSTATE CANCER

This early-phase trial tests a new treatment called PSMA-UCAR T cells for men with advanced prostate cancer that no longer responds to standard therapies. The therapy uses specially engineered immune cells to target a protein (PSMA) on cancer cells. The main goal is to check safe…

This early-stage study tests a new drug called ARX517, alone or with other treatments, in men with metastatic prostate cancer (cancer that has spread). The main goal is to check the drug's safety and find the best dose. About 183 men will take part in this study.

This early-stage study tests two oral drugs (darolutamide and abemaciclib) plus standard hormone therapy in men with high-risk prostate cancer that has spread or may come back. The first part finds the safest dose; the second part checks if the combination can shrink tumors befor…

This early-stage trial tests whether two oral drugs, talazoparib and tazemetostat, can be safely combined to treat metastatic castration-resistant prostate cancer (mCRPC), a form of prostate cancer that has spread and stopped responding to hormone therapy. About 35 participants w…

This study tests a new drug called AZD5305 given together with standard hormone therapies for men whose prostate cancer has spread. The main goals are to check safety, find the right dose, and see early signs of whether the combination helps control the cancer. About 174 men with…

This study tests a new drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 125 adults with cancers like glioblastoma, melanoma, breast, or prostate ca…

This study tests whether giving denosumab every 12 weeks instead of every 4 weeks is just as effective at preventing bone complications (like fractures or spinal cord compression) in people with metastatic breast or prostate cancer. About 1,380 participants will be followed to co…

This study looks at whether adding a high-dose, precise type of radiation called SBRT to usual treatments (like hormone therapy or chemo) can delay cancer progression in people with 1 to 5 bone metastases from breast, lung, or prostate cancer. About 168 adults aged 18-75 with goo…

This study tests whether a combination of two drugs (cabozantinib and atezolizumab) works better than standard hormone therapy for men with advanced prostate cancer that has stopped responding to initial hormone treatment. About 575 men with metastatic castration-resistant prosta…

This early-stage study tests whether adding a chemotherapy drug (carboplatin) to a targeted radiation therapy (177Lu-PSMA-617) is safe and effective for men with advanced prostate cancer that has stopped responding to hormone therapy. About 37 participants will receive the combin…

This study tests whether adding the immunotherapy drug atezolizumab and targeted radiation (SBRT) to standard hormone therapy can better control metastatic prostate cancer that hasn't been treated yet. About 28 men will receive the combination and be followed for 2 years to see i…

This study tests a mix of four drugs (nivolumab, ipilimumab, cabazitaxel, and carboplatin) in men with a rare, aggressive form of prostate cancer. The goal is to see if the combination can stop or slow the cancer from growing. Participants receive up to 10 cycles of the combo, th…

This study tests a new imaging agent, 18F-DCFPyL, to see if it can better find prostate cancer that has spread in the body compared to a standard scan. About 96 adults with metastatic prostate cancer will receive both types of PET scans. The goal is to improve detection of cancer…

This study tests a radioactive tracer called 18F-DCFPyL to see if it can better find prostate cancer that has spread or come back after treatment. About 360 men with high-risk or recurrent prostate cancer will get a PET/CT scan using this tracer. The goal is to improve how doctor…

This observational study looks at 15 specific proteins on prostate cancer cells to understand how common they are and whether they can predict survival. Researchers will study tissue samples from 1,600 men with different types of prostate cancer, including those that have spread.…

This study looks at whether a blood test can help doctors choose the most effective treatment for men with metastatic prostate cancer. Researchers will analyze blood samples from 192 patients during their standard care to track cancer-related markers. The goal is not to test a ne…

This study watches how prostate cancer tumors change while patients are on hormone therapy. Researchers take small tissue samples (biopsies) before and during treatment to see what makes the cancer stop responding. The goal is to find new targets for future treatments. 30 men wit…

This study checks if a special type of PET scan (PSMA PET) is more accurate than usual scans for seeing prostate cancer and how it responds to treatment. About 58 people with prostate cancer that is new or getting worse will take part. The goal is to see if this scan can better p…

This study tracks how well treatment is working in men with metastatic hormone-sensitive prostate cancer using special PET scans (PSMA-PET). Twenty participants will get a scan before starting standard therapy and another after 6 months. The goal is to see if these scans can help…

This study looks at how two different prostate cancer medications, darolutamide and enzalutamide, affect thinking skills like memory and attention. About 111 men with advanced prostate cancer will take one of the two drugs and complete computer-based brain tests over time. The go…